Similar to α-GLY, pancreatic α-amylase (α-AMY)is another key enzyme in the digestive system that is responsiblefor breaking down long-chain carbohydrates to glucose, therefore becominganother target in the management of T2DM.8,9 Therefore,the inhibition of α-GLY and α-AMY enzymes may be a potentialtreatment strategy for T2DM. The gene discussed is SHMT2; the disease is type 2 diabetes mellitus.